Developing Potential Treatments for a Variety of Tumor Types

Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. We are currently conducting clinical trials to evaluate pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer.

Partnering, Collaborating & Combining Towards the Future

Oncolytics will grow through partnerships and collaborations, including:

  • Co-development agreement with Pfizer & Merck KGaA to evaluate their PD-L1 checkpoint inhibitor Bavencio® in combination with pelareorep in HR+/HER2- metastatic breast cancer.
  • Master supply agreement with Roche to supply Tecentriq® - their PD-L1 checkpoint inhibitor – in support of Oncolytics’ clinical development programs. The first program is the AWARE-1 study in breast cancer, a collaboration with the cooperative group SOLTI. The second is the GOBLET study, designed to evaluate pelareorep with Tecentriq® in gastrointestinal (GI) cancers, specifically pancreatic, colorectal, and anal, which is being managed by the cooperative group AIO.
  • Combination studies with Merck’s PD-1 checkpoint inhibitor Keytruda® in both multiple myeloma and pancreatic cancer.
  • Combination study with Bristol-Myers Squibb’s PD-1 checkpoint inhibitor Opdivo® in multiple myeloma.
  • Partnership with Adlai Nortye in China to develop pelareorep for metastatic breast cancer, as well as additional indications.
  • Combination study with Incyte’s PD-1 checkpoint inhibitor retifanlimab in triple-negative breast cancer.

We continue to investigate further collaboration and partnership opportunities, particularly with additional immuno-oncology agents, including CAR T cell therapies, bispecific antibodies, and CDK4/6 and PARP inhibitors.


Pelareorep is currently being manufactured at commercial scale in its final formulation under a commercial supply agreement with MilliporeSigma.